Search

Your search keyword '"Bláha V"' showing total 21 results
Start Over Author "Bláha V" Database Supplemental Index
21 results on '"Bláha V"'

1. Lipoprotein Apheresis in the Treatment of Dyslipidemia - the Czech Republic Experience.

Author

BLÁHA, V., BLÁHA, M., LÁNSKÁ, M., SOLICHOVÁ, D., KUJOVSKÁ KRČMOVÁ, L., HAVEL, E., VYROUBAL, P., ZADÁK, Z., ŽÁK, P., and SOBOTKA, L.

Subjects
DYSLIPIDEMIA, LIPOPROTEINS, PLASMA exchange (Therapeutics), PLASMAPHERESIS, THERAPEUTICS
Abstract

In 1984, we started using therapeutic plasmapheresis (plasma exchange) as a method of extracorporeal lipoprotein elimination for the treatment of hypercholesterolemic patients. We evaluated the results of long-term therapy in 14 patients, 8 men and 6 women. The average age was 55.6±13.2 (range 28-70), median 59.5 years. 14 patients were diagnosed with familial hypercholesterolemia (FH): 5 homozygous, 9 heterozygous. Ten patients in the group were treated using immunoadsorption lipoprotein apheresis and 4 using hemorheopheresis. Immunoapheretic interventions decreased LDL-cholesterol (82±1 %), ApoB (73±13 %) and even Lp(a) by 82±19 %, respectively. Selected non-invasive methods are important for long-term and repeated follow-up. Carotid intima-media thickness showed improvement or stagnation in 75 % of the patients. Biomarkers of endothelial dysfunction such as endoglin (in the control group: 3.85±1.25 μg/l, in lipoprotein apheresis-treated hypercholesterolemic individuals 5.74±1.47 μg/l), CD40 ligand (before lipoprotein apheresis: 6498±2529 ng/l, after lipoprotein apheresis: 4057±2560 ng/l) and neopterin (before lipoprotein apheresis: 5.7±1.1 nmol/l, after lipoprotein apheresis: 5.5±1.3 nmol/l) related to the course of atherosclerosis, but did not reflect the actual activity of the disease nor facilitate the prediction or planning of therapy. Hemorheopheresis may improve blood flow in microcirculation in familial hypercholesterolemia and also in some other microcirculation disorders via significantly decreased activity of thrombomodulin (p<0.0001), tissue factor (p<0.0001), aggregation of thrombocytes (p<0.0001) and plasma and whole blood viscosity (p<0.0001). In conclusion, lipoprotein apheresis and hemorheopheresis substantially lowered LDL-cholesterol in severe hypercholesterolemia. Our experience with long-term therapy also shows good tolerance and a small number of complications (6.26 % non-serious clinical complications). [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

2. Familial Hypercholesterolemia in the Czech Republic: More Than 17 Years of Systematic Screening Within the MedPed Project.

Author

VRABLÍK, M., VACLOVÁ, M., TICHÝ, L., SOŠKA, V., BLÁHA, V., FAJKUSOVÁ, L., ČEŠKA, R., ŠATNÝ, M., and FREIBERGER, T.

Subjects
HYPERCHOLESTEREMIA, LOW density lipoproteins, METABOLISM, EARLY diagnosis
Abstract

Familial hypercholesterolemia (FH) is the most common autosomal dominant disorder. It is characterized by a decrease in LDL cholesterol catabolism and an early clinical manifestation of atherosclerotic vessel damage. The aim of the MedPed (Make early diagnosis to Prevent early deaths) project is an early diagnosis of FH patients in order to profit from early treatment and prevent cardiovascular events. Till November 30, 2016 The Czech National MedPed Database has registered 7,001 FH patients from 5,223 different families that is 17.4 % of expected patients in the Czech Republic considering 1:250 FH prevalence. The improvement in diagnostic accuracy, patient cooperation and above all familial cascade screening is enabled by FH mutation detection using the modern technology of next-generation sequencing. FH still remain undiagnosed even though the Czech Republic is one of the most successful countries with respect to FH detection. The opportunities of international collaboration and experience sharing within international programs (e.g. EAS FHSC, ScreenPro FH etc.) will improve the detection of FH patients in the future and enable even more accessible and accurate genetic diagnostics. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

3. The Role of VEGF in the Diabetic Patients Undergoing Endovascular Therapy of Symptomatic Aortic Valve Stenosis.

Author

BLÁHA, V., SÍÁSEK, J., BIS, J., FORTUNATO, J., ANDRYS, C., PAVLÍK, V., POLANSKY, P., BRTKO, M., and SOBOTKA, L.

Subjects
VASCULAR endothelial growth factor receptors, PEOPLE with diabetes, ENDOVASCULAR surgery, SYMPTOMS, AORTIC stenosis treatment
Abstract

The aim of this study was to explore changes in plasma vascular endothelial growth factor (VEGF) In aged patients who undergone transcatheter aortic valve implantation or balloon angioplasty for the treatment of aortic stenosis. Plasma VEGF was measured in subjects with diabetes mellitus type 2 (DM) (n=21, age 79.2±1.6 years) and in non-diabetic subjects (non-DM) (n=23, age 84.4±0.7 years), using an EUSA kit. Before the procedure plasma levels of VEGF were significantly lower in DM than in non-DM patients (P<0.05). Plasma VEGF significantly increased in both groups (DM and non-DM) 24 h (387±64 vs. 440±30 pg/ml, P<0.05) and 72 h (323±69 vs. 489±47 pg/ml, P<0.05) after the endovascular procedure. However, the VEGF in DM patients was significantly lower compared to non-DM subjects up to one month after the endovascular procedure (283±47 vs. 386±38 pg/ml, P<0.05). We conclude that increased plasma VEGF in aged patients associates with atherosclerotic aortic valve stenosis. In spite of that plasma VEGF in DM was constantly significantly lower than in non diabetic patients, both before and after the endovascular procedure, possibly reflecting a disturbance of angiogenic/antiangiogenic balance in diabetes. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

6. The antibiotic resistance survey: a preliminary report on the drug utilization evaluation study at the University Teaching Hospital, Charles University, Czech Republic

Author

Vlček, J., Šleszarová, P., Pozlerová, E., Kotlář, J., Bláha, V., and Mashburn, J.

Abstract

To perform a longitudinal drug utilization evaluation and to analyse the antibiotic resistance patterns of Pseudomonas aeruginosa as well as the consumption of selected antibiotics. Data from 1992–1997 were collected from the Hospital Pharmacy database at the University Teaching Hospital (1200 beds) where physicians' prescriptions are recorded. To analyse antibiotic consumption, ATC/DDD methodology was used. To express the dynamics of the drug consumption, the value of index I was established. To analyse the resistance patterns of Pseudomonas aeruginosa, data from the antibiotic centre database at The Teaching Hospital were examined. The rate of consumption is on the rise among extend spectrum aminopenicillins, carbapenems, glycopeptides, third generation cephalosporins and second generation macrolides and fluoroquinolones. Antibiotics with a decline in the rate of consumption are first generation macrolides and tetracyclines. The consumption of relatively new and expensive antibiotics increased during the observation period between 1992–1997. Resistance of Pseudomonas aeruginosa to selected antibiotics was identified to be increasing. In the case of amikacin and ceftazidime a possible association between resistance and consumption was found. Copyright © 2000 John Wiley & Sons, Ltd.

Published
2000

7. Abstracts of papers and posters advanced activities in pharmaceutical care 24th European Symposium on Clinical Pharmacy

Author

Nahata, M. C., Bootman, J. L., Zadák, Z., Soeters, P. B., Goldberg, Laurence A., Stremetzne, S., Jaehde, U., Streit, M., Kreuser, E. D., Thiel, E., Schunack, W., Calvert, R. T., Feely, M., Chrystyn, H., Mangues, M. A., Ginovart, G., Moral, M. A., Lopes, A. P., Farré, R., Demestre, X., Altirriba, O., Kloft, Ch., Beyer, J., Steuer, J., Siegert, W., Bever, J., Bialer, M., Sussan, S., Salach, O. Abu, Danenberg, H. D., Laor, A., Barnett, M. I., Cosslett, A. G., Cohen, J., Marini, P., Bassi, C., Bonzanini, A., Cassani, T., Dalle Ore, G., Mangiante, G., Scroccaro, G., Kaczan, M., Eriksen, J., Toft, B., Jandová, M., Vlček, J., Klemerová, V., Sobotka, L., Ayestarán, A., López, R., Montoro, J. B., Pou, L., Estíbalez, A., Pascual, B., Aumente, M. D., Panadero, M. D., Caraballo, M., Pozo, J. C., Perez, J. L., Falcão, A. C., Fernández de Gatta, M. M., Dominguez-Gil, A., Caramona, M. M., Lanao, J. M., Fendrich, Z., Zajic, J., Bellés, Medall M. D., Casabó, Alós V. G., Jiménez, Torres N. V., Hervás, Botella M. A., Abad, Gimeno F. J., Casterá, Melchor D. E., Aminian, M., Mangues, M. A., Clopés, A., Branco, C., Badell, I., Pardo, N., Palací, C., Bonal, J., Rialp, G., Bara, B., Nobilis, M., Bláha, V., Havel, E., Květina, J., Brátová, M., Solichová, D., Mullerova, M., Svoboda, D., Pokrajac, M., Miljković, B., Simić, D., Brzaković, B., Galetin, A., Pinheiro, R. L., Carrondo, A. P., Sieradzki, E., Strauss, K., Olejarz, E., Marzec, A., Kaużny, J., Szymura-Oleksiak, J., Wyska, E., Jarosz, B., Kosowicz, I., Fabirkiewicz, K., Cherian, R., Vodoz, A. -L., Imsand, B., Belli, D., Rochat, Th., Müllerová, H., Falcão, F., Carvalho, A., Pereira, T., Fonseca, C., Freitas, O., Resende, M., Parrinha, A., Costa, M., Pessanha, M. A., Ferreira, A., Mourão, L., Ceia, F., Lima, Mendonça, Tavares, R., SalesLuis, A., Carlos, Santos, Pereira, M. E. Araújo, Carmo, J. Alves do, Lacerda, J. M. Forjaz, Morais, J. A., Beaufils, C., Le Duff, M., Zamparutti, P., Assicot, P., Bohor, M., Angelini, B., Lambert, M., Manelli, J. C., Gayte-Sorbier, A., Bongrand, M. C., Timon-David, P., Fiqueira, I. C., Lourenco, R., Silva, P. A., Rodrigues, M. O., Fischer, A., Schorr, W., Radziwill, R., Lihtamo, M., Jäppinen, A., Tuovinen, K., Pekkala, M., Nuutinen, L., Morató, L., Lorente, L., Muñoz, J., Monges, Ph, Blancard, A., Lacarelle, B., Denis, J. P., Bongrand, M. -C., Penot-Ragon, Ch, Gouin, F., Petitcollot, Nicole, Tinguely, I., Beney, J., Marty, S., Reymond, J. -Ph., Bussels, J., Robays, H., Litzinger, A., Rohda-Bohler, R., Salek, M. S., Turpin, S., Derby, E., Millar, B., Maggs, C., Santiago, L. M., Batel, Marques, Cajaraville, G., Tarnés, M. J., Díaz, M. J., Del Pozo, C., Plazaola, A., Vuelta, M., Díaz-Munío, E., Ferrer, A., Lozano, A., Guerra, R., Pontón, J. L., Robays, H., Kint, K., Verstraetep, A., Eini, D. El, Ojala, R. K., Kontra, K. M., Naaranlahti, T. J. P., Martorell, M., Oliveras, M., Juste, C., Lopez, M. T., Hidalgo, E., Cabañas, M. J., Barroso, C., Llop, J. M., Rey, M., Diaz-Munio, E., Pastó, L., Tubau, M., Gómez-Bellver, M. J., Rodriguez, J., Gómez, J. M., Gónzalez, M. L., Gol, V., Fuentes, V., Ramón, S., Girona, L., Castelló, T., Olona, M., García, L., Girón, C., Monteserín, C., Gonzalez, P., Alberola, C., Feio, J. A. L., Pharm, D., Batel Marques, F. J., Borges, Alexandrino M., Salek, S., Escoms, M. C., Caro, I., Ticó, N., Hidalgo, M., Bruguera, R., Jodar, R., Dowell, J. M., Davey, P. G., Malek, M., Díaz-Munío, E., Vuelta, M., Pastó, L., Rev, M., Ferrer, I., Llop, J. M., Marti, T., Ibars, M., Delporte, J. P., Ansseau, M., Albert, A., Sibourg, M., Gaspard, O., Deprez, M., Ndougsa, H. M., Poma, M., Tamés, M. J., Macek, K., Vlček, J., Fendrich, Z., Klejna, M., Dhillon, S., Castro, I., Newton, M., Zupanets, I. A., Chernyh, V. P., Bezdetko, N. B., Popov, S. B., Velieva, M. N., Babajeya, S. M., Mamedov, Y. D., Mammedov, Y. Dj., Veliev, P. M., Nasudari, A. A., Bandalieva, A. A., Nordbo, S., Smith-Solbakken, M., Myklctun, R., Berge, W., Thormodsen, M., Zupanets, L. A., Kicenko, L. S., Plusch, S. I., Isaev, S. G., Vokrouhlický, L., Souček, R., Kuneš, P., Nývlt, O., Potselueva, L. A., Egorova, S. N., Kadirova, E. A., Ziganshina, L. E., Chaloupka, J., and Genger, K.

Published
1995
Full Text
View/download PDF

8. Distribution of fenofibric acid in lipoprotein fractions of patients

Author

Nobilis, M., Kvetina, J., Anzenbacher, P., Vontor, T., Svoboda, D., Brátová, M., Solichová, D., Zadák, Z., Bláha, V., and Vlcek, J.

Abstract

Summary: The antidyslipidemic agent fenofibrate (procetofen) is hydrolysedin vivo to its, main active metabolite — fenofibric (procetofenic) acid. This metabolite is usually determined in pharmacokinetic studies, because plasma concentrations of fenofibrate are practically undetectable. Presented study is focussed on the distrubution of fenofibric acid into lipoprotein (VLDL, LDL, IDL and HDL) fractions of human and (for comparison) minipig blood plasma, which has not been studied yet. In order to obtain more accurate results, a new HPLC method based on the use of newly synthetized internal standards was developed. Four homologues of fenofibric acid prepared have identical chromophoric part of their molecules and hence the same UV spectra as fenofibric acid. From this point of view, these standards are more suitable for determination of fenofibric acid than the formerly used ones — naproxen or bezafibrate. Fenofibric acid levels in the high density lipoprotein fraction has been shown to be significantly higher (in both human and minipig plasma) than in the other lipoprotein fractions. This fact may be explained by higher affinity of the fenofibric acid to proteins constituting major part of the high density lipoprotein fraction.

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results